Supplementary information
=========================

 {#Sec1}

**Additional file 1.** Full Protocol.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
=========================

**Supplementary information** accompanies this paper at 10.1186/s13063-020-04430-y.

We thank the China National Center for Biotechnology Development and all the hospitals involved in the clinical research mentioned above.

GW, HZ designed the trial. JL drafted the manuscript. CZ and ZW participated in the proofreading of the paper. The author(s) read and approved the final manuscript.

Under the deployment of the scientific research team in response to COVID-19 \'s epidemic of the State Council, China National Center for Biotechnology Development undertakes the drug research and organizes Peking University First Hospital to lead the research. The project number of this COVID-19 emergency project: 2020YFC0846800. The study funders had no role in study design; collection, analysis, and interpretation of data and in writing the manuscript.

The datasets generated during and/or analyzed during the current study will be available from the author (e-mail: john131212\@126.com) on reasonable request.

This study was approved by the ethics committee of Peking University First Hospital on April 13, 2020, decision No 2020 research 112. Informed consent to participate will be obtained from all participants.

Not applicable.

The authors declare that they have no competing interests
